Research Article
İnme Profilaksisi Nedenli Varfarin ya da Yeni Oral Antikoagulan Kullanan Hastalarda Depresyon Anksiyete ve Yaşam Kalitesi Arasındaki İlişkinin Değerlendirilmesi
Abstract
Amaç: Bu çalışmada kardiyoembolik inme
riski olan hastalarda proflaksi amaçlı varfarin yâda yeni oral antikoagulan
(YOAK) kullanan hastalarda depresyon, anksiyete ve yaşam kalitesi düzeylerini
değerlendirmeyi amaçladık.
Gereç ve Yöntemler: Kesitsel Çalışmamıza Nisan
2016-Ağustos 2016 yılları arasında 40-70 yaş arasındaki non valvüler AF si olan
kardiyoembolik inme riski nedenli proflaksi amaçlı en az 6 aydır varfarin ya da
YOAK kullanan toplam 200 hasta (100 varfarin, 100 YOAK) dâhil edildi. Her iki
grupta belirlenen hastaların demografik özellikleri ile beraber tüm hastalarla
psikyatrik tanıları tespit etmek amaçlı psikyatrik görüşme yapıldıktan sonra
sosyodemografik formla birlikte depresyon ve anksiyete düzeyini belirlemek
amaçlı Beck Depresyon Ölçeği ve Beck Anksiyete Ölçeği uygulandı. Yaşam
kalitesini değerlendirme amaçlı ise Dünya Sağlık Örgütü Yaşam Kalitesi Ölçeği
Kısa Formu (WHOQOL-BREF-) ölçeği uygulandı.
Bulgular: Çalışmamızda varfarin
kullananlarda depresyon ve anksiyete düzeyleri YOAK kullananlara göre yüksek
bulunurken yaşam kalitesi düzeyi ise daha düşük bulunmuştur. Aynı zamanda
varfarin kullanım süresi arttıkça depresyon ve anksiyete düzeylerinde artış,
yaşam kalitesi düzeyinde ise azalma saptanmıştır.
Sonuç: YOAK grubu ilaçların varfarine
göre, daha düşük depresyon ve anksiyete düzeyleri ile ilişkili olduğu ayrıca
YOAK grubu ilaç kullanan hastalar, daha yüksek yaşam kalitesine sahip
oldukları söylenebilir.
References
- REFERENCES
- 1. Goldstein LB, Adams R, Alberts MJ ve ark. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-1633 2. Go A. S., Mozaffarian D., Roger V. L., Benjamin E. J., Berry J. D., Blaha M. J., et al. 2014. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014; 129:28–2923. Turker Y, Ekinozu I, Aytekin S, Turker Y, Basar C, Baltaci D, Kaya E Comparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in PatientsWith Atrial Fibrillation. Clin Appl Thromb Hemost. 2015 Aug 14. pii: 1076029615600792. [Epub ahead of print]4. Coban E, Ataklı D, Soysal A , Kırbas D Quality of Life of Patients Under Anticoagulant Therapy Compared to Patients Treated with Antiplatelet Therapy. Arch Neuropsychiatr 2016 • DOI: 10.5152/npa.2016.15950 5. Graven C, Brock K, Hill KD, Cotton S, Joubert L.First Year After Stroke: An Integrated Approach Focusing on Participation Goals Aiming to Reduce Depressive Symptoms Stroke. 2016 Nov;47(11):2820-2827. Epub 2016 Oct 13. 6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.7. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESCv Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747.8. Turker Y, Ongel K, Ozaydin M, Turker Y, Yildirim Bas F, Akkaya M. Mechanical prosthetic valve disease is related with an increase in depression and anxiety disorder. Med Glas (Zenica). 2015;12(1): 86-92.9. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632-636. 10. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571.11. Hisli N. Validation of Beck Depression Inventory for Univercity Students Journal of Psychicology Turkish1989; 7:3-13.12. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56:893-89713. Ulusoy M, Şahin N, Erkmen H. Turkishversion of The Beck Anxiety Inventory: Psychometric properties. J CognPsychother 1998; 12:28-35.
- 14. The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46:1569–85.15. Eser SY, Fidaner H, Fidaner C et al. Measure of quality of life WHOQOL-100 and WHOQOL-Bref. Journal of 3P 1999;7(2 Suppl.):5-13.16. Kılıcoglu A. Risk factors and etiology of depression among elderly: a review. Anatolian Journal of Psychiatry 2006;7:49-54.17. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000; 356(9224):97-102.18. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost. 2004;2:584-591.19. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156(16):1829–1836.20. Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005;21(7):1085-1090. 21. Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LYsub-study. Int J Cardiol. 2013 Oct 3;168(3):2540-7. doi: 10.1016/j.ijcard.2013.03.059. Epub 2013 May 822. Michal M, Prochaska JH, Keller K, et al. Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program. Int J Cardiol. 2015;187:614-619.
Year 2018,
, 568 - 574, 30.09.2018
Abstract
References
- REFERENCES
- 1. Goldstein LB, Adams R, Alberts MJ ve ark. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-1633 2. Go A. S., Mozaffarian D., Roger V. L., Benjamin E. J., Berry J. D., Blaha M. J., et al. 2014. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014; 129:28–2923. Turker Y, Ekinozu I, Aytekin S, Turker Y, Basar C, Baltaci D, Kaya E Comparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in PatientsWith Atrial Fibrillation. Clin Appl Thromb Hemost. 2015 Aug 14. pii: 1076029615600792. [Epub ahead of print]4. Coban E, Ataklı D, Soysal A , Kırbas D Quality of Life of Patients Under Anticoagulant Therapy Compared to Patients Treated with Antiplatelet Therapy. Arch Neuropsychiatr 2016 • DOI: 10.5152/npa.2016.15950 5. Graven C, Brock K, Hill KD, Cotton S, Joubert L.First Year After Stroke: An Integrated Approach Focusing on Participation Goals Aiming to Reduce Depressive Symptoms Stroke. 2016 Nov;47(11):2820-2827. Epub 2016 Oct 13. 6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.7. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESCv Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747.8. Turker Y, Ongel K, Ozaydin M, Turker Y, Yildirim Bas F, Akkaya M. Mechanical prosthetic valve disease is related with an increase in depression and anxiety disorder. Med Glas (Zenica). 2015;12(1): 86-92.9. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632-636. 10. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571.11. Hisli N. Validation of Beck Depression Inventory for Univercity Students Journal of Psychicology Turkish1989; 7:3-13.12. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56:893-89713. Ulusoy M, Şahin N, Erkmen H. Turkishversion of The Beck Anxiety Inventory: Psychometric properties. J CognPsychother 1998; 12:28-35.
- 14. The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46:1569–85.15. Eser SY, Fidaner H, Fidaner C et al. Measure of quality of life WHOQOL-100 and WHOQOL-Bref. Journal of 3P 1999;7(2 Suppl.):5-13.16. Kılıcoglu A. Risk factors and etiology of depression among elderly: a review. Anatolian Journal of Psychiatry 2006;7:49-54.17. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000; 356(9224):97-102.18. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost. 2004;2:584-591.19. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156(16):1829–1836.20. Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005;21(7):1085-1090. 21. Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LYsub-study. Int J Cardiol. 2013 Oct 3;168(3):2540-7. doi: 10.1016/j.ijcard.2013.03.059. Epub 2013 May 822. Michal M, Prochaska JH, Keller K, et al. Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program. Int J Cardiol. 2015;187:614-619.
There are 3 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | September 30, 2018 |
| Submission Date | July 3, 2018 |
| Published in Issue | Year 2018 |
Cite
SMJ'de yayınlanan makaleler, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı kapsamında lisanslanır